Publication date: Jul 29, 2024
Vaccination can be viewed as comprising the most important defensive barriers to protect susceptible groups from infection. However, vaccine hesitancy for COVID-19 is widespread worldwide. We aimed to systematically review studies eliciting the COVID-19 vaccine preference using discrete choice experiments. A literature search was conducted in PubMed, Embase, Web of Science, Scopus, and CINAHL Plus platforms in April 2023. Search terms included discrete choice experiments, COVID-19, and vaccines and related synonyms. Descriptive statistics were used to summarize the study characteristics. Subgroup analyses were performed by factors such as high-income countries and low- and middle-income countries and study period (before, during, and after the pandemic wave). Quality appraisal was performed using the 5-item Purpose, Respondents, Explanation, Findings, and Significance checklist. The search yield a total of 623 records, and 47 studies with 53 data points were finally included. Attributes were grouped into 4 categories: outcome, process, cost, and others. The vaccine effectiveness (21/53, 40%) and safety (7/53, 13%) were the most frequently reported and important attributes. Subgroup analyses showed that vaccine effectiveness was the most important attribute, although the preference varied by subgroups. Compared to high-income countries (3/29, 10%), a higher proportion of low- and middle-income countries (4/24, 17%) prioritized safety. As the pandemic progressed, the duration of protection (2/24, 8%) during the pandemic wave and COVID-19 mortality risk (5/25, 20%) after the pandemic wave emerged as 2 of the most important attributes. Our review revealed the critical role of vaccine effectiveness and safety in COVID-19 vaccine preference. However, it should be noticed that preference heterogeneity was observed across subpopulations and may change over time. PROSPERO CRD42023422720; https://tinyurl. com/2etf7ny7.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | VO | vaccination |
disease | MESH | infection |
disease | VO | vaccine |
disease | VO | COVID-19 vaccine |
disease | IDO | quality |
disease | IDO | process |
disease | VO | vaccine effectiveness |
disease | VO | time |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Methylphenidate |
disease | VO | organization |
disease | MESH | emergency |
disease | VO | effective |
disease | VO | population |
disease | IDO | production |
disease | MESH | infectious diseases |
disease | IDO | intervention |
drug | DRUGBANK | Methionine |
disease | MESH | uncertainty |
disease | IDO | country |
disease | VO | effectiveness |
disease | VO | Canada |
drug | DRUGBANK | Etoperidone |
disease | VO | vaccine efficacy |